These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

94 related articles for article (PubMed ID: 3901897)

  • 1. Phagocytosis and killing of GBS in an experimental animal model.
    Holm SE; Bergholm AM; Wagner B; Wagner M
    Antibiot Chemother (1971); 1985; 35():201-10. PubMed ID: 3901897
    [No Abstract]   [Full Text] [Related]  

  • 2. Experimental infection with group B streptococci in tissue cages implanted in rabbits.
    Wagner M; Wagner B; Bergholm AM; Holm SE
    Zentralbl Bakteriol Mikrobiol Hyg A; 1984 Dec; 258(2-3):242-55. PubMed ID: 6397945
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cellular and humoral aspects of host defense mechanisms against GBS.
    Gotoff SP; Boyer KM
    Antibiot Chemother (1971); 1985; 35():142-56. PubMed ID: 3901891
    [No Abstract]   [Full Text] [Related]  

  • 4. Intravenous administration of human IgG to newborn infants: changes in serum antibody levels to GBS.
    Christensen KK; Christensen P; Seger RA
    Antibiot Chemother (1971); 1985; 35():247-53. PubMed ID: 3901901
    [No Abstract]   [Full Text] [Related]  

  • 5. Intrapulmonary bacterial clearance of type III group B streptococcus is reduced in preterm compared with term rabbits and occurs independent of antibody.
    Hall SL; Sherman MP
    Am Rev Respir Dis; 1992 May; 145(5):1172-7. PubMed ID: 1586063
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Neonatal mouse model of group B streptococcal infection.
    Rodewald AK; Onderdonk AB; Warren HB; Kasper DL
    J Infect Dis; 1992 Sep; 166(3):635-9. PubMed ID: 1500748
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunoglobulin therapy of neonatal group B streptococcal infections: an overview.
    Fischer GW
    Pediatr Infect Dis J; 1988 May; 7(5 Suppl):S13-6. PubMed ID: 3041355
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Methods of assessment and importance of opsonic activity for GBS.
    Hill HR; Shigeoka AO; Rote NS; Allred CD; Hemming VG
    Antibiot Chemother (1971); 1985; 35():157-69. PubMed ID: 3901892
    [No Abstract]   [Full Text] [Related]  

  • 9. Group B streptococcal lung infection in neonatal rabbits.
    Sherman M; Goldstein E; Lippert W; Wennberg R
    Pediatr Res; 1982 Mar; 16(3):209-12. PubMed ID: 7038607
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Maternal humoral immunity and neonatal GBS infection: studies in a primate model.
    Hemming VG; London WT; Curfman BL; Patrick DF; Fischer GW
    Antibiot Chemother (1971); 1985; 35():194-200. PubMed ID: 3901896
    [No Abstract]   [Full Text] [Related]  

  • 11. Vaccination With a Latch Peptide Provides Serotype-Independent Protection Against Group B Streptococcus Infection in Mice.
    Lin SM; Jang AY; Zhi Y; Gao S; Lim S; Lim JH; Song JY; Sullam PM; Rhee JH; Seo HS
    J Infect Dis; 2017 Dec; 217(1):93-102. PubMed ID: 29106586
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Monoclonal antibodies targeting different cell wall antigens of group B streptococcus mediate protection in both Fc-dependent and independent manner.
    Senn BM; Visram Z; Meinke AL; Neubauer C; Gelbmann D; Sinzinger J; Hanner M; Lundberg U; Boisvert H; Reinscheid D; von Gabain A; Nagy E
    Vaccine; 2011 May; 29(24):4116-24. PubMed ID: 21496467
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A polyclonal human IgG preparation hyperimmune for type III, group B Streptococcus: in vitro opsonophagocytic activity and efficacy in experimental models.
    Givner LB; Edwards MS; Baker CJ
    J Infect Dis; 1988 Oct; 158(4):724-30. PubMed ID: 3049837
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Group B streptococci escape host immunity by deletion of tandem repeat elements of the alpha C protein.
    Madoff LC; Michel JL; Gong EW; Kling DE; Kasper DL
    Proc Natl Acad Sci U S A; 1996 Apr; 93(9):4131-6. PubMed ID: 8633028
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immune response to type III group B streptococcal polysaccharide-tetanus toxoid conjugate vaccine.
    Kasper DL; Paoletti LC; Wessels MR; Guttormsen HK; Carey VJ; Jennings HJ; Baker CJ
    J Clin Invest; 1996 Nov; 98(10):2308-14. PubMed ID: 8941648
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pooled human IgG hyperimmune for type III group B streptococci: evaluation against multiple strains in vitro and in experimental disease.
    Givner LB; Baker CJ
    J Infect Dis; 1991 May; 163(5):1141-5. PubMed ID: 2019763
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Type III group B streptococcal strain differences in susceptibility to opsonization with human serum.
    Fischer GW; Hunter KW; Wilson SR
    Pediatr Res; 1981 Dec; 15(12):1525-9. PubMed ID: 7033908
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The R-proteins.
    Christensen KK; Christensen P
    Antibiot Chemother (1971); 1985; 35():114-8. PubMed ID: 3901888
    [No Abstract]   [Full Text] [Related]  

  • 19. A new flow-cytometry-based opsonophagocytosis assay for the rapid measurement of functional antibody levels against Group B Streptococcus.
    Fabbrini M; Sammicheli C; Margarit I; Maione D; Grandi G; Giuliani MM; Mori E; Nuti S
    J Immunol Methods; 2012 Apr; 378(1-2):11-9. PubMed ID: 22309986
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Monoclonal antibody preparations for immunotherapy of experimental GBS infection.
    Shigeoka AO; Pincus SH; Rote NS; Pritchard DG; Santos JI; Hill HR
    Antibiot Chemother (1971); 1985; 35():254-66. PubMed ID: 3901902
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.